15 studies found for:    removab
Show Display Options
Rank Status Study
1 Completed
Has Results
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Condition: Ovarian Cancer
Intervention: Drug: catumaxomab
2 Completed Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
Conditions: Gastric Cancer;   Gastric Adenocarcinoma
Interventions: Drug: Catumaxomab;   Drug: catumaxomab
3 Recruiting Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Drug: Catumaxomab
4 Recruiting Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis;   Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis;   Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
Interventions: Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel;   Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel
5 Completed Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
Conditions: EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast);   Malignant Ascites
Interventions: Biological: Catumaxomab (Removab);   Procedure: paracentesis
6 Completed Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
Condition: Malignant Ascites Due to Epithelial Carcinoma
Intervention: Drug: catumaxomab
7 Completed CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Conditions: Cancer;   Neoplasms;   Carcinoma;   Malignant Ascites
Interventions: Drug: Catumaxomab;   Drug: Prednisolone
8 Completed
Has Results
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Condition: Malignant Ascites
Intervention: Drug: catumaxomab
9 Terminated A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Condition: Epithelial Cancer Patients
Intervention: Drug: catumaxomab
10 Unknown  Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission
Condition: Ovarian Cancer
Intervention: Drug: Catumaxomab
11 Completed Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer
Intervention: Drug: Catumaxomab
12 Completed Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention: Biological: anti-EpCAM x anti-CD3 (removab)
13 Recruiting Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab
Condition: Patients With Gastric Peritoneal Carcinomatosis
Interventions: Drug: Catumaxomab 100µg;   Drug: Catumaxomab 140µg
14 Completed Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
Conditions: Gastric Cancer;   Gastric Adenocarcinoma
Intervention: Drug: catumaxomab
15 Active, not recruiting Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Conditions: Malignant Ascites;   Gastrointestinal Cancers
Interventions: Drug: Bevacizumab;   Other: Placebo

Indicates status has not been verified in more than two years